Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 29, 2010 Brian Orelli	A Prescription to Investigate Further Let's not worry just yet about Medco's margins.
The Motley Fool February 17, 2005 Stephen D. Simpson	Caremark Hits the Mark Again With expectations of higher than 25% growth in 2005, the pharmacy benefits manager looks like it will continue to take care of its investors.
The Motley Fool February 16, 2005 Brian Gorman	Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies?
The Motley Fool November 2, 2005 Brian Gorman	Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note.
The Motley Fool July 27, 2004 Brian Gorman	Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans.
The Motley Fool April 19, 2011 Bryan White	Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies.
The Motley Fool July 30, 2009 Brian Orelli	A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money.
The Motley Fool November 3, 2010 Brian Orelli	A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it.
Managed Care November 2005	Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market.
Managed Care September 2005 Martin Sipkoff	Mail Order Pharmacy Saves Money, Says PCMA, but at What Cost? The savings to consumers and employers are apparent, but are health plans left holding the bag in mail-order pharmacy?
The Motley Fool August 31, 2011 Shubh Datta	CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue.
The Motley Fool November 4, 2009 Brian Orelli	This One Is Thriving in a Recession Saving customers money makes it easy for Medco.
The Motley Fool February 25, 2009 Brian Orelli	The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers.
The Motley Fool February 14, 2005 Brian Gorman	GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision.
The Motley Fool February 15, 2006 Stephen D. Simpson	Good Marks for Caremark The pharmacy benefits management company should have even more positive operating leverage left in the tank. Investors, take note.
The Motley Fool December 6, 2007 Selena Maranjian	Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall.
The Motley Fool June 10, 2010 Claire Stephanic	CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers.
The Motley Fool November 2, 2006 Ryan Fuhrmann	CVS Blazes a New Healthcare Trail Strong third-quarter earnings aside, the merger announcement with pharmacy benefit manager Caremark was the real shocker here. Investors, take note.
The Motley Fool April 27, 2005 Brian Gorman	Cautious on Medco Medco's earnings were respectable, but for now investors may want to step back.
The Motley Fool May 4, 2011 Jason Knapp	Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will.
The Motley Fool October 28, 2010	Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool October 24, 2006 Brian Gorman	Medco's Fringe Benefits Recent developments will present some challenges, but Medco remains a solid long-term investment.
The Motley Fool June 13, 2005 Brian Gorman	Walgreen Strikes Back The traditional drugstore operator is expanding its mail-order business. This should be a welcome sign to investors.
The Motley Fool August 1, 2008 Brian Orelli	Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line.
Managed Care May 2002	Study: Mail Order Pharmacy Keeps Growing in Popularity The tech-savvy may denigrate it as "snail mail," but patients see value in reaching into their mailboxes for pharmaceuticals
The Motley Fool May 8, 2007 Ryan Fuhrmann	CVS/Caremark Tie the Knot While it's too early to see if CVS blazed a new health-care trail by combining a drugstore chain with giant pharmacy benefit manager Caremark, there are still interesting tidbits to pass along to investors from recently reported results.
The Motley Fool October 27, 2005 Stephen D. Simpson	Can ESRX Spell P-r-o-f-i-t-s? A company focused on lowering medical costs sounds like a good idea, but investors should dig deeper. While pharmaceutical benefits manager Express Scripts offers high growth and high valuation, it may also offer higher-than-average risk.
BusinessWeek May 9, 2005 Weintraub & Barrett	BW 50: Can Caremark's Health Hold Up? Caremark Rx Inc. faces a growing set of legal and market challenges, but Its drug-benefit business is soaring, and its CEO remains upbeat about the future.
The Motley Fool March 6, 2009 Brian Orelli	Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now?
The Motley Fool April 30, 2008 Brian Orelli	Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs.
Managed Care June 2003 Thomas Kaye	Mail Order Pharmacy -- Savings or Added Cost? Mail order programs can provide savings, but HMOs need to ensure that they are actually receiving sufficient value.
The Motley Fool March 22, 2010 Dave Mock	A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
The Motley Fool June 2, 2011 Dee Gill	CVS's Improved Performance Begins to Drown Out the Dump-Caremark Chants Is the prognosis for CVS looking up?
The Motley Fool August 3, 2007 Ryan Fuhrmann	CVS Caremark Is No Sicko Pharmacy powerhouse CVS Caremark is looking to blaze a new health-care trail with the recent merger of their drugstore and pharmacy benefit management operations.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool February 23, 2006 Stephen D. Simpson	Express Scripts Overdue for a Pause This pharmacy benefits manager is posting very good growth and has room for improvement, but what about the stock price?
The Motley Fool September 26, 2006 Ryan Fuhrmann	Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers?
The Motley Fool June 29, 2006 Ryan Fuhrmann	Walgreen's Prescription for Growth The drugstore chain continues to roll, even if it is a bit pricey. Great companies rarely trade at bargain-basement levels. But if savvy investors keep a watchful eye, they may find an opportunity to pick up some shares at a fairer price.
The Motley Fool February 28, 2005 Brian Gorman	Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending.
The Motley Fool December 19, 2006 Brian Gorman	Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note.
The Motley Fool January 12, 2010 Dayana Yochim	6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab.
The Motley Fool February 4, 2008 Timothy M. Otte	CVS Has Major Mo' Fourth-quarter results cap a stellar year for the drugstore retailer.
The Motley Fool June 14, 2010 Jennifer Schonberger	The S&P 500's Biggest Movers Gannett was among the companies making a move up.
The Motley Fool October 2, 2011 Shubh Datta	Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment?
Managed Care January 2007 Martin Sipkoff	Employers Want Plans & PBMs To Push Hard for Generics Health insurers' aggressive stand on members' use of generic drugs can attract new clients, but does it interfere with the physician-patient relationship?
Managed Care May 2006 John Carroll	Effective Ways To Increase Usage of Generics Generics is one of the few areas where insurance plans can economize effectively. BlueCross & BlueShield of North Carolina is one of many insurers that are changing members' and prescribers' behavior.
BusinessWeek March 7, 2005 Amy Barrett	A Drug Company On Growth Hormones By adding Accredo to its portfolio, Medco gains a strong presence in the area of specialty drugs. Investors sent Medco's stock down slightly on news of the deal. But they give company chief David B. Snow Jr. credit for putting Medco in a position to capitalize on new opportunities.
CFO June 1, 2010 Alix Stuart	"This Is the Era of Smarter Medicine." A prescription-drug provider says it can thrive even as it helps drive down health-care costs. An interview with Richard Rubino, CFO, Medco Health Solutions Inc.